Patents
Literature
19 results about "Ebola virus" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Ebola virus is one of five known viruses within the genus Ebolavirus. Four of the five known ebolaviruses, including EBOV, cause a severe and often fatal hemorrhagic fever in humans and other mammals, known as Ebola virus disease. Ebola virus has caused the majority of human deaths from EVD, and is the cause of the 2013–2014 Ebola virus epidemic in West Africa, which has resulted in at least 17,145 suspected cases and 6,405 confirmed deaths. Ebola virus and its genus were both originally named for Zaire, the country where it was first described, and was at first suspected to be a new "strain" of the closely related Marburg virus. The virus was renamed "Ebola virus" in 2010 to avoid confusion. Ebola virus is the single member of the species Zaire ebolavirus, which is the type species for the genus Ebolavirus, family Filoviridae, order Mononegavirales. The natural reservoir of Ebola virus is believed to be bats, particularly fruit bats, and it is primarily transmitted between humans and from animals to humans through body fluids. The EBOV genome is a single-stranded RNA approximately 19,000 nucleotides long.
Ebola virus social simulation system based on generative agent
The invention discloses a generative agent-based Ebola virus social simulation system and a generative agent-based Ebola virus social simulation method, which are used for dynamically simulating the interactive influence of social behaviors and virus propagation by integrating an SEIR infectious disease model and a generative agent framework. The system comprises a social factor interaction module, an experimental scene configuration module and a dynamic analysis module, supports high-fidelity simulation of scenes such as management scheme deviation and resource allocation optimization, and can quantitatively evaluate social chain reactions (for example, the infection rate is reduced by 30%-40%) of prevention and control measures. According to the method, the defect that a traditional model ignores social complexity is overcome, a prospective experimental platform is provided for policy making of social sensitive infectious diseases such as Ebola, and the method is adapted and expanded to other infectious disease research.
Owner:YUNNAN UNIV
NPL3 polypeptide and application thereof
The invention discloses an NPL3 polypeptide and application thereof. The invention discloses an NPL3 polypeptide or a pharmaceutical salt thereof. The amino acid sequence of the NPL3 polypeptide is as shown in SEQ ID NO. 1. The invention also discloses a DPS4-NPL3 fusion polypeptide. The fusion polypeptide comprises a DPS4 protein, the NPL3 polypeptide and a flexible peptide connecting the DPS4 protein and the NPL3 polypeptide. Experimental results show that the NPL3 peptide has a good inhibiting effect on the Ebola virus and acts on a binding interface of the Ebola virus VP30 and NP to play a role. The invention proposes that the NPL3 peptide can be used as a potential medicine for resisting the Ebola virus for the first time. Under the condition that specific anti-Ebola drugs are limited, a new thought and method are provided for research and development of the anti-Ebola drugs.
Owner:ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY
2-[(7-hydroxy-8-methyl-2-oxochromen-4-yl)methylsulfanyl]-4,6-dimethylpyridine-3-carbonitrile for use in the treatment of ebola virus
ActiveCN120267670BStrong anti-infection effectEnhanced inhibitory effectOrganic active ingredientsAntiviralsCarbamateEbola virus
The application of 2-[(7-hydroxy-8-methyl-2-oxochrome-4-yl)methylthiosulfase]-4,6-dimethylpyridine-3-carbamate in the treatment of Ebola virus belongs to the field of pharmaceutical technology. This invention addresses the technical problem of the lack of effective anti-Ebola virus drugs in the prior art by providing 2-[(7-hydroxy-8-methyl-2-oxochrome-4-yl)methylthiosulfase]-4,6-dimethylpyridine-3-carbamate, which can effectively inhibit Ebola virus replication within a non-toxic range. The compound exhibits good anti-infective effects against SUDV, BDBV, and TAFV viruses and can be used to prepare safe and effective broad-spectrum anti-Ebola virus drugs.
![2-[(7-hydroxy-8-methyl-2-oxochromen-4-yl)methylsulfanyl]-4,6-dimethylpyridine-3-carbonitrile for use in the treatment of ebola virus](https://images-eureka.patsnap.com/patent_img/0b17398c-dbd6-4402-8aa3-7f16a05d292f/CN120267670B.png "2-[(7-hydroxy-8-methyl-2-oxochromen-4-yl)methylsulfanyl]-4,6-dimethylpyridine-3-carbonitrile for use in the treatment of ebola virus")
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE +1
Stable antibody formulation
PendingUS20250288665A1Immunoglobulins against virusesPharmaceutical delivery mechanismAntiendomysial antibodiesEbola virus
The present disclosure provides stable pharmaceutical formulations comprising a human antibody that specifically binds to Ebola Virus (EBOV). In certain embodiments, the formulations contain, in addition to an anti-EBOV antibody, a buffer, an amino acid, a non-ionic surfactant, and a stabilizer. The pharmaceutical formulations of the present disclosure exhibit a substantial degree of antibody stability upon stress, for example, agitation during transport, and storage, for example, storage at temperatures greater than 40° C.
Owner:REGENERON PHARMACEUTICALS INC
Replicon Compositions and Methods of Using Same for the Treatment of Diseases
PendingUS20250281602A1SsRNA viruses negative-senseSsRNA viruses positive-senseAntigenReplication competent virus
The present invention embraces compositions comprising at least two RNA replicons (self-amplifying RNA vectors (saRNAs or rRNAs)) that can be replicated by a replicase of a self-replicating virus, e.g., a replicase of alphavirus origin. Of the at least two replicons, at least one of which optionally comprises an open reading frame encoding for the RNA-dependent RNA polymerase or replicase that is able to replicate each of the at least two replicons. Further, each replicon comprises an open reading frame encoding for different antigens of interest, e.g., different antigens derived from the same or from different pathogenic organisms, for example the glycoprotein and nucleoprotein of Ebola virus.
Owner:BIONTECH SE +2
Antiviral compounds
PendingUS20260109724A1Organic active ingredientsGroup 5/15 element organic compoundsEbola virusHcv hepatitis c virus
The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, ebola, Zika, West Nile, Dengue, and HCV.
Owner:GILEAD SCIENCES INC
HUMAN ANTIBODIES AGAINST EBOLA VIRUS GLYCOPROTEIN
Owner:REGENERON PHARMACEUTICALS INC
Nano antibody ZC2 targeting Ebola virus and application thereof
The invention discloses a CDR region of a nano antibody targeting an Ebola virus. The invention also discloses a nano antibody ZC2, which comprises the CDR region of the nano antibody targeting the Ebola virus. The invention also discloses a fusion protein antibody. The invention also discloses a polynucleotide, an expression vector, a host cell and an antibody conjugate. The invention also discloses application of the CDR region of the nano antibody, the nano antibody ZC2, the fusion protein antibody and the antibody conjugate. The invention also discloses a pharmaceutical composition. The CDR region of the nano antibody targeting the Ebola virus, the nano antibody ZC2 and the fusion protein antibody can be combined with GP proteins in different pH environments, so that the stability is very good; the potential of efficiently neutralizing the ZEBOV type Ebola virus is achieved, and the neutralizing effect can reach the picomole level.
Owner:UNIV OF SCI & TECH OF CHINA
NEUTRALIZING ANTIBODIES AGAINST EBOLA VIRUS GLYCOPROTEIN AND THEIR USE
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
Use of 4,4'-(benzo[c][1,2,5]thiadiazole-4,7-diyl)diphenylamine compounds in the preparation of anti-ebola virus drugs
4,4'-(benzo[C][1,2,5]thiadiazole-4,7-diyl)dianiline compound in the preparation of anti-Ebola virus drugs belongs to the technical field of medicines.The present application provides 4,4'-(benzo[C][1,2,5]thiadiazole-4,7-diyl)dianiline compound to solve the technical problem of lack of effective anti-Ebola virus drugs in the prior art, and the molecular formula of the compound is C 18 H 14 N4S.The 4,4'-(benzo[C][1,2,5]thiadiazole-4,7-diyl)dianiline compound provided by the present application can effectively inhibit the replication and infection of Ebola virus in the non-toxic range, and has good anti-infection effect on Sudan virus SUDV, Bundibugyo virus BDBV and Taï Forest virus TAFV, and the compound can be applied to prepare safe and effective broad-spectrum anti-Ebola virus drugs.
![Use of 4,4'-(benzo[c][1,2,5]thiadiazole-4,7-diyl)diphenylamine compounds in the preparation of anti-ebola virus drugs](https://images-eureka.patsnap.com/patent_img/63d14fb4-32a9-4c34-828b-9e5a4427f47c/CN119732952B.png "Use of 4,4'-(benzo[c][1,2,5]thiadiazole-4,7-diyl)diphenylamine compounds in the preparation of anti-ebola virus drugs")
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE +1
Experimental method for heating inactivation and effect evaluation of Ebola virus
PendingCN120683058ASsRNA viruses negative-senseMicrobiological testing/measurementEbola virusImmunofluorescence
The invention belongs to the technical field of biological safety, and particularly relates to an experimental method for heating inactivation of Ebola viruses and evaluation of the effect of the Ebola viruses. According to a dynamic inactivation parameter model established by Ebola virus strain characteristics, aggregation state, culture medium components, initial titer and equipment heat transfer efficiency, calculating the time required for inactivation; according to the inactivation effect evaluation method, TCID50 is combined with immunofluorescence and PMA-qRT-PCR parallel detection is adopted, the verification period is effectively shortened, meanwhile, three-generation blind transmission is initiated for the first time and combined with qRT-PCR detection for biological safety verification, the sensitivity is improved to 101 TCID50 / mL, and the false negative risk is thoroughly eliminated.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
4' - halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
PendingJP2026027247AOrganic active ingredientsSugar derivativesEastern equine encephalitis virusNucleotide
To provide pharmaceutical compositions and methods for the treatment of viral infections.SOLUTION: Halogen-containing nucleotide and nucleoside therapeutic compositions and uses related thereto are disclosed. In certain embodiments, the disclosure relates to the treatment or prevention of viral infections. Such viral infections may include togaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, eastern equine encephalitis, western equine encephalitis, and Venezuelan equine encephalitis (EEE, WEE, and VEE, respectively), chikungunya (CHIK), Ebola, flu, RSV, and Zika virus infections.SELECTED DRAWING: Figure 1
Owner:EMORY UNIVERSITY
Antiviral compounds
ActiveCN115087659BOrganic active ingredientsGroup 5/15 element organic compoundsZika virusEbola virus
The present disclosure provides compounds for the treatment of a variety of diseases such as respiratory syncytial virus (RSV), HRV, hMPV, Ebola virus, Zika virus, West Nile virus, Dengue fever, and HCV.
Owner:GILEAD SCIENCES INC
Purine nucleotide and nucleoside therapeutic compositions and uses related thereto
Disclosed are purine nucleotide and nucleoside therapeutic compositions therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include enterovirus, tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.
Owner:EMORY UNIVERSITY
Nanoparticle vaccines with novel structural components
The present invention provides novel nanoparticle presented vaccine compositions that are stabilized with a locking domain. Various immunogens can be employed in the preparation of the vaccine compositions, including viral immunogens such as HIV-1 and Ebola viral immunogens, and non-viral immunogens such as immunogens derived from bacteria, parasites and mammalian species. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating viral infections.
Owner:THE SCRIPPS RES INST
4'-halogen-containing nucleotide and nucleoside therapeutic compositions and related uses
PendingJP2026062641AOrganic active ingredientsSugar derivativesEastern equine encephalitis virusNucleotide
To provide a novel treatment for viral infections. [Solution] Halogen-containing nucleotide and nucleoside therapeutic compositions and related uses are disclosed. In certain embodiments, the disclosure relates to the treatment or prevention of viral infections. Such viral infections may include Togaviridae, Bunyaviridae, Arenaviridae, Coronaviridae, Flaviviridae, Picornaviridae, Eastern equine encephalitis, Western equine encephalitis, and Venezuelan equine encephalitis (EEE, WEE, and VEE, respectively), Chikungunya fever (CHIK), Ebola, influenza, RSV, and Zika virus infection. In exemplary embodiments, the compound is selected from the following: TIFF2026062641000590.tif42170
Owner:EMORY UNIVERSITY
Human antibodies against Ebola virus glycoproteins
To provide human antibodies to Ebola virus glycoproteins.SOLUTION: The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies, and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the Ebola virus for preventing viral attachment and / or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.SELECTED DRAWING: None
Owner:REGENERON PHARMACEUTICALS INC
CRISPR-Cas13 system targeting Ebola GP gene and used for inhibiting Ebola virus replication and application of CRISPR-Cas13 system
The invention belongs to the field of biomedicine, and discloses a CRISPR-Cas13 system targeting an Ebola GP gene and used for inhibiting Ebola virus replication and application of the CRISPR-Cas13 system. The technical problem to be solved by the invention is how to inhibit the replication of the Ebola virus. According to the CRISPR-Cas13 system for inhibiting the replication of the Ebola virus, disclosed by the invention, the CRISPR-Cas13 system contains crRNA, and the target sequence of the crRNA is SEQ ID No.1 in a sequence table. Experimental results prove that the crRNA provided by the invention can target the genome sequence of the Ebola virus, can reduce the protein level of the virus gene, and also can degrade the targeted virus gene, so that the replication ability of the virus is inhibited. The crRNA and the CRISPR-Cas13 system composed of the crRNA can be used for treating and / or preventing diseases caused by the Ebola virus.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES
Peptides and peptide microarrays for detection and differentiation of antibody responses to ebola virus
Peptides, platforms and methods for detecting antibody responses to filovirus infections, detecting antibody responses to EBOV infection, and detecting antibody responses to vaccination by EBOV vesicular stomatitis virus-based vaccine.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES +1